A phase 1/2 study evaluating the efficacy and safety of the oral CXCR4 inhibitor X4P-001 in combination with axitinib in patients with advanced renal cell carcinoma.

A phase 1/2 study evaluating the efficacy and safety of the oral CXCR4 inhibitor X4P-001 in combination with axitinib in patients with advanced renal cell carcinoma. Article

Full Text via DOI: 10.1200/JCO.2018.36.15_suppl.4510 Web of Science: 000442916002037

International Collaboration

Vaishampayan, Ulka N.; McDermott, David F.; Matrana, Marc Ryan; Rha, Sun Young; Zurita, Amado J.; Thai Huu Ho; Keam, Bhumsuk; Lee, Jae-Lyun; Joseph, Richard Wayne; Ali, Sarah; Stadler, Walter Michael; Haas, Naomi B.; Sundararajan, Srinath; Park, Se Hoon; Mowat, Rex B.; Picus, Joel; Dudek, Arkadiusz Z.; Zakharia, Yousef; Gan, Lu; Atkins, Michael B.